Free Trial
NASDAQ:LXEO

Lexeo Therapeutics Q3 2026 & Study result Earnings Results & Report

Lexeo Therapeutics logo
$2.87 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$3.61 +0.74 (+25.78%)
As of 08:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lexeo Therapeutics missed analyst earnings expectations in its Q3 2026 & Study result results, released November 16, 2026. The company reported EPS of -$0.43 versus the -$0.33 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026 & Study result
Time
Before Market Opens
Conference Call
8:00 AM ET
Live Event
Earnings Conference Call
Lexeo Therapeutics Q3 2026 & Study result
00:00 / 00:00
Live Transcript
Follow Audio

Lexeo Therapeutics EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.33
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Lexeo Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Lexeo Therapeutics' Q4 2026 earnings is estimated for Monday, December 14, 2026, based on past reporting schedules

Lexeo Therapeutics Q3 2026 & Study result Earnings FAQ

Lexeo Therapeutics (NASDAQ:LXEO) reported earnings of -$0.43 per share for Q3 2026 & Study result, missing the consensus estimate of -$0.33. The report was announced on Monday, November 16, 2026.

Lexeo Therapeutics' next earnings date is estimated for Monday, December 14, 2026. MarketBeat tracks confirmed and estimated earnings dates for Lexeo Therapeutics on the company's earnings history page.

Lexeo Therapeutics Earnings Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Lexeo Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lexeo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexeo Therapeutics and other key companies, straight to your email.

About Lexeo Therapeutics

Lexeo Therapeutics (NASDAQ:LXEO) is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations.

The company’s investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products.

Founded in 2017, Lexeo is based in New York and conducts research and clinical development in the United States. As a clinical-stage company, it focuses on advancing its pipeline rather than marketing approved therapies.

View Lexeo Therapeutics Profile